In 2008 there were fewer than a dozen IPOs in the life science sector. 

In today’s volatile biotechnology, pharmaceutical, and health IT sectors investors face ever-evoling challenges that can make the generation of exceptional returns increasingly difficult.  

Life science investors now have to take on the responsibililty to ensure each phase of development is successfully executed in order to maximize the ROI potential across their investment portfolio.


ACCUGENEX Consulting is a multifaceted consulting firm that provides a broad range of development, regulatory, and business services to drive successful drug, device, diagnostic & health IT product development.  Within these ever-evolving procesess defined by scientific, regulatory and legislative parameters, AccuGenex uses our 60 years of scientific and drug development experience to identify biotech/pharma product opportunities, and provides the comprehensive services needed to define & support successful development and life-cycle management plans.

ACCUGENEX works with inventors, venture capitalists, university technology transfer offices, and emerging biotech to help focus and maximize effective outcomes to their project needs.

 
Focus Areas: